Akero Therapeutics Revenue
Biotechnology Research • 
South San Francisco, California, United States • 51-100 Employees
Akero Therapeutics revenue & valuation
| Annual revenue | $6,502,180 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $20,900,000 |
| Total funding | $491,100,000 |
Key Contacts at Akero Therapeutics
Valerie Fenster
Senior Director, Packaging & Human Factors Engineering
Jinjin Zhang
Director
Nicholas Chepkurgor
Sr. Director, Sox & Sec Reporting
Erik Tillman
Associate Director, Translational Biology And Pharmacology
Neha Bhatia
Sr. Director, Sox Head Of Sox Compliance
Thomas Quinn
Senior Director, Controller
Chris Tse
Director, Regulatory Affairs
Amol Palande
Associate Director, Statistical Programming
Lina Patel
Director, Quality Control
Jacob Kraus
Associate Director Of Analytical Development, Cmc
Company overview
| Headquarters | 601 Gateway Blvd, Suite 350, South San Francisco, California 94080, US |
| Phone number | +16504876488 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Founded | 2017 |
| Employees | 51-100 |
| Socials |
Akero Therapeutics Email Formats
Akero Therapeutics uses 4 email formats. The most common is {first name} (e.g., john@akerotx.com), used 58.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name} | john@akerotx.com | 58.1% |
{first name}{last name} | johndoe@akerotx.com | 21% |
{first initial} | j@akerotx.com | 14.5% |
{first initial}{last name} | jdoe@akerotx.com | 6.5% |
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), as well as three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH or compensated cirrhosis due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4). Akero is headquartered in South San Francisco. Special Advisory: Job applicants should be aware of online recruitment scams, including fraudulent interviews and fake job offers. Akero does not conduct interviews through text messages or messaging apps, will never request money from applicants, and communicates only via emails ending with "@akerotx.com." Please verify that any communication claiming to be from Akero comes from an official company email address. If you receive any suspicious messages, submit a report to the Federal Trade Commission.
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Akero Therapeutics has 50 employees across 9 departments.
Departments
Number of employees
Funding Data
Explore Akero Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Akero Therapeutics Tech Stack
Discover the technologies and tools that power Akero Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Video players
Security
Security
Form builders
JavaScript libraries
JavaScript libraries
Caching
Mobile frameworks
JavaScript libraries
JavaScript libraries
Maps
JavaScript libraries
Ireland
Portugal
Hungary
Italy
United Kingdom
Viet NamFrequently asked questions
4.8
40,000 users
